Hormonal

Lanreotide

Also known as: Somatuline, Somatuline Depot

FDA Approved
Share:

Key Facts: Lanreotide

Category
Hormonal
FDA Status
FDA Approved
Clinical Status
FDA Approved - Acromegaly and GEP-NETs
Administration
Deep subcutaneous injection
Typical Dose
60-120 mg every 4 weeks
Frequency
Every 4 weeks (deep SC)
Duration
Long-term / chronic use
Also Known As
Somatuline, Somatuline Depot

Mechanism of Action

Like octreotide, lanreotide binds the somatostatin receptor family with a strong preference for SSTR2 and SSTR5 and weak binding to SSTR1, SSTR3, and SSTR4. Hitting SSTR2 and SSTR5 on pituitary cells suppresses growth hormone release, which lowers IGF-1 and controls acromegaly. On neuroendocrine tumor cells, which often carry plenty of these same receptors, the drug both reduces hormone over-secretion and exerts a direct antiproliferative, growth-slowing effect. The supersaturated gel formulation forms a depot under the skin that releases the peptide slowly, so a single injection lasts about four weeks. The clinical logic is identical to octreotide: a stable, receptor-selective stand-in for a hormone the body destroys in minutes.

Research Summary

Lanreotide has solid human trial evidence, not just preclinical data. The landmark CLARINET phase 3 trial, published in the New England Journal of Medicine in 2014, randomized over 200 patients with metastatic grade 1 or 2 enteropancreatic neuroendocrine tumors and showed lanreotide cut the risk of progression or death by 53 percent, with progression-free survival not reached versus about 18 months on placebo. That result made it one of the first somatostatin analogs proven to actually slow neuroendocrine tumor growth, not just ease symptoms. In acromegaly, multicenter studies show it normalizes IGF-1 and lowers growth hormone in a substantial fraction of patients, comparable to octreotide. Side effects mirror the class: diarrhea, gallstones, and injection-site reactions. The evidence base is mature and the drug is widely used in oncology and endocrinology.

Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosing

Community experience

Common Dose

60-120 mg every 4 weeks

Range

60-120 mg per injection

Frequency

Every 4 weeks (deep SC)

Long-acting somatostatin analog. Somatuline Depot. Deep subcutaneous injection.

Research Dosing

Scientific studies

FDA-approved dosing

Doses from Studies

60-120 mg deep SC every 4 weeks

FDA Approved Labeling - Prescribed dose

Extended interval dosing possible

FDA Approved Labeling - Prescribed dose

Duration

Long-term / chronic use

Administration

Deep subcutaneous injection

Timing & Administration

Best Time to Take

Morning or as directed

Follow recommended protocol

Food Recommendation

With or without food

Why This Timing?

Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Diarrhea
  • Abdominal pain
  • Nausea
  • Injection site reactions
  • Gallstones
  • Hyperglycemia or hypoglycemia
  • Bradycardia
  • FDA approved (Somatuline)

References

Research This Peptide Further

Frequently Asked Questions

What does Lanreotide do?

Lanreotide is an eight-amino-acid somatostatin analog, a close cousin of octreotide, given as a long-acting deep-injection gel (Somatuline Depot/Autogel) usually once a month. It is FDA-approved for acromegaly and for gastroenteropancreatic neuroendocrine tumors, and it carries an approval for carcinoid syndrome. It is established prescription medicine, not an experimental compound.

How does Lanreotide work?

Like octreotide, lanreotide binds the somatostatin receptor family with a strong preference for SSTR2 and SSTR5 and weak binding to SSTR1, SSTR3, and SSTR4. Hitting SSTR2 and SSTR5 on pituitary cells suppresses growth hormone release, which lowers IGF-1 and controls acromegaly. On neuroendocrine tumor cells, which often carry plenty of these same receptors, the drug both reduces hormone over-secretion and exerts a direct antiproliferative, growth-slowing effect. The supersaturated gel formulation forms a depot under the skin that releases the peptide slowly, so a single injection lasts about four weeks. The clinical logic is identical to octreotide: a stable, receptor-selective stand-in for a hormone the body destroys in minutes.

Is Lanreotide FDA approved?

Yes, Lanreotide is FDA approved. FDA Approved - Acromegaly and GEP-NETs

What are the side effects of Lanreotide?

Reported side effects include: Diarrhea, Abdominal pain, Nausea, Injection site reactions, Gallstones. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Lanreotide?

Community-reported common dose: 60-120 mg every 4 weeks (Every 4 weeks (deep SC)). Range: 60-120 mg per injection. Administration: Deep subcutaneous injection. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Lanreotide or used in similar applications.

Pegvisomant

FDA

Pegvisomant (brand name Somavert) flips the usual acromegaly strategy on its head: instead of telling the tumor to make less growth hormone, it blocks growth hormone's receptor on target tissues directly. It is a PEGylated, genetically modified version of human growth hormone that acts as a receptor antagonist, FDA-approved in 2003 for acromegaly patients who do not respond well to surgery or other drugs. It is the single most effective option for normalizing IGF-1, which is why it is a key second-line therapy.

Hormonal

Gonadorelin

FDA

Gonadorelin is a synthetic copy of natural GnRH (gonadotropin-releasing hormone), a 10-amino-acid peptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that tells the pituitary to release LH and FSH. It is FDA-approved for evaluating pituitary function and has historical use in inducing ovulation. In the peptide world it is mostly used off-label to keep the testes working during testosterone replacement, and the catch is that timing matters enormously: pulse it and you stimulate, give it continuously and you shut the system down.

Hormonal

Leuprolide

FDA

Leuprolide (brand name Lupron) is a synthetic GnRH agonist, a modified peptide about 20 times more potent than natural GnRH, and it is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The clever part is counterintuitive: it works by overstimulating the GnRH system so hard that the pituitary shuts down sex hormone production. It is a real, long-established prescription drug, not a research peptide, and it carries meaningful side effects from the low-hormone state it creates.

Hormonal

Octreotide

FDA

Octreotide is a synthetic eight-amino-acid mimic of the natural hormone somatostatin, the body's main 'off switch' for hormone secretion. It shuts down excess growth hormone, so it is a frontline FDA-approved drug for acromegaly, and it also tames the flushing and diarrhea of hormone-secreting carcinoid and other neuroendocrine tumors. This is real, approved medicine with decades of clinical data behind it, sold as Sandostatin (injectable, since 1988), Sandostatin LAR (monthly depot), and Mycapssa (oral capsule, approved 2020).

Hormonal

Macimorelin

FDA

Macimorelin (brand name Macrilen) is an orally active ghrelin receptor agonist used as a diagnostic test, not a treatment. You drink a single dose, then doctors measure how much growth hormone the pituitary releases to diagnose adult growth hormone deficiency. It was FDA approved in December 2017 as the first oral diagnostic agent for that condition.

Hormonal

Kisspeptin

Clinical Trials

Kisspeptin is the master switch that tells your brain to start reproduction. It is a family of peptides (the full length is kisspeptin-54, with shorter active fragments KP-14, KP-13, and KP-10) made from the KISS1 gene, and it acts as the upstream trigger for the entire reproductive hormone cascade. It is not an approved drug, but it has been tested in real human trials for fertility, hypothalamic amenorrhea, and male hypogonadism, with promising early results.

Hormonal

Want updates on Lanreotide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.